Also known as Apelin-13 · [Pyr1]apelin-13 · APJ ligand
The endogenous ligand of the apelin receptor — a short C-terminal fragment studied as a vasodilator and inotrope, and as a metabolic signal.
Research refreshed
65 residues · single-letter amino-acid sequence
Apelin is the peptide ligand of the apelin receptor (APLNR, formerly the orphan receptor APJ). The gene APLN encodes a 77-residue prepropeptide that is cut to several active fragments — apelin-36, apelin-17, and apelin-13 — all sharing the same C-terminus. Apelin-13 (QRPRLSHKGPMPF) is the fragment used as a defined research peptide; in plasma its N-terminal glutamine usually cyclizes to pyroglutamate, giving [Pyr1]apelin-13, the predominant circulating form. It is not an approved medicine.
Apelin was isolated in 1998 by Tatemoto and colleagues from bovine stomach extracts as the endogenous ligand of APJ, a receptor O’Dowd’s group had cloned in 1993 because it resembles the angiotensin AT1 receptor. Angiotensin does not bind it. The human precursor (UniProt Q9ULZ1) is 77 residues; proteolytic processing releases apelin-36, apelin-17, and apelin-13, and the N-terminal glutamine of apelin-13 cyclizes spontaneously to pyroglutamate. That pyroglutamyl species, [Pyr1]apelin-13, is the form measured in human plasma and the one used in most human infusion studies.
The cardiovascular findings are what brought the peptide back into active drug research. In healthy volunteers and in patients with chronic heart failure, intravenous [Pyr1]apelin-13 increased cardiac output while lowering peripheral resistance (Japp et al., Circulation 2010). The same receptor also has a second endogenous ligand, elabela (gene APELA, also called toddler), required for embryonic heart development. A separate biochemical link keeps the pathway in the literature: ACE2, the enzyme that converts angiotensin II, also clips the C-terminal phenylalanine from apelin and thereby weakens it.
Outside the heart, apelin is studied in energy metabolism and fluid balance. Preclinical and small human studies report improved insulin sensitivity, and the receptor is expressed in hypothalamic circuits that regulate drinking and blood pressure. Native fragments last only minutes in plasma, so the molecules now in development are stabilized peptide analogs and small-molecule agonists rather than apelin-13 itself. None is FDA-approved.
Agonist at the class A GPCR APLNR. Coupling through Gi/o lowers cAMP; the receptor also engages Gq and β-arrestin. In endothelium this raises nitric oxide and dilates resistance vessels; in cardiomyocytes it is a positive inotrope. ACE2 removes the C-terminal phenylalanine, and the resulting des-Phe peptide is a weaker agonist.
Behind every vial of Apelin is the same exacting pipeline every research peptide runs — but the chemistry plays out differently for this molecule. Here is how Apelin, specifically, is brought into being.
On paper, Apelin is C69H111N23O16S — about 1,550.8 daltons of precisely arranged atoms. Before a single bond is made, the target sequence, salt form, and purity threshold are written down as the contract the finished material must meet.
Apelin's chain is short but unusual — it carries non-natural residues that help it resist enzymatic breakdown, but demand specialized, costlier building blocks and careful coupling on the synthesizer.
The crude mixture — Apelin plus its deletions and side products — is then separated on preparative HPLC, and where the cut is taken decides the difference between a genuinely pure peptide and a barely-passable one.
A real batch of Apelin proves itself: identity confirmed by mass spectrometry against its ~1,550.8 Da, purity read directly off an analytical HPLC trace, water and counterion content measured. That batch-specific certificate of analysis is the only honest way to know what is actually in a vial of Apelin — and a short, cold, accountable chain of custody is how that purity survives the trip to your bench.
Apelin-13 is a 13-residue solid-phase synthesis with a free C-terminal acid — routine chain assembly, with two identity problems that define the batch. The N-terminal glutamine cyclizes to pyroglutamate on its own, so a specification has to state whether the product is apelin-13 (CAS 217082-58-1, C69H111N23O16S, 1550.8 Da) or [Pyr1]apelin-13 (CAS 217082-60-5, C69H108N22O16S, 1533.8 Da). Methionine oxidation is the other impurity to quantify; the C-terminal phenylalanine must stay intact, because loss of that residue is the ACE2 inactivation product and it weakens receptor activity.
Don't judge a vial by its cake. A fluffy, good-looking lyophilized powder reflects bulking agents and freeze-drying parameters — not purity. Insist on a batch-specific certificate of analysis.
Recent clinical trials and publications mentioning Apelin, pulled automatically from ClinicalTrials.gov and PubMed and refreshed daily. Listings are unfiltered search results, not curated endorsements.
Apelin is the peptide hormone that activates the apelin receptor (APLNR, formerly APJ). The research material is usually the 13-residue C-terminal fragment, apelin-13, or its pyroglutamate form, [Pyr1]apelin-13.
Apelin-13 begins with glutamine (QRPRLSHKGPMPF, CAS 217082-58-1, 1550.8 Da). That glutamine cyclizes to pyroglutamate, losing ammonia, to give [Pyr1]apelin-13 (CAS 217082-60-5, 1533.8 Da). The pyroglutamate form is the predominant species in human plasma.
Cardiovascular physiology (vasodilation and increased cardiac output), insulin sensitivity, and fluid balance. A second ligand of the same receptor, elabela, is studied in heart development. No apelin product is FDA-approved.
No — this is a research and educational reference, not dosing guidance.
The once-weekly GLP-1 receptor agonist behind Ozempic, Wegovy, and Rybelsus — FDA-approved for type 2 diabetes, chronic weight management, cardiovascular risk reduction, and MASH.
ViewThe once-daily GLP-1 agonist that preceded semaglutide — FDA-approved for diabetes (Victoza) and obesity (Saxenda).
ViewDual GIP / GLP-1 receptor agonist with industry-leading weight-loss endpoints.
ViewDosing protocols, mechanism, comparisons, and the latest trials — citation-backed answers grounded in PubMed, PubChem, and ClinicalTrials.gov.